BACKGROUND: Viral infections constitute a primary trigger for asthma exacerbations. While vaccines protect against viral infections by eliciting a Th1 immune response, the impact of the asthmatic immune milieu which is characterized by Th2 cytokine dominance and elevated IgE levels on post-vaccination antibody production remains elusive. Therefore, vaccination protocols tailored to asthma patients need to be formulated. METHODS: The levels of IgG specific for SARS-CoV-2 S protein were measured in the sera of vaccinated and unvaccinated individuals by ELISA. The differences in antibody titers between asthma patients and healthy controls, as well as among distinct asthma subgroups were analyzed. RESULTS: The vaccinated individuals had significantly elevated serum antibody levels compared to their unvaccinated counterparts. There were no significant differences in the antibody titers of asthma patients and healthy controls after completion of the three-dose vaccination regimen. Furthermore, no discernible variations in antibody titers were detected among the asthma subgroups. CONCLUSION: Asthma patients can safely adhere to the same vaccination strategies as the general healthy population, negating the need for any specialized vaccination protocols based solely on the asthmatic immune landscape.